{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:32:46Z","timestamp":1780468366343,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC1181 and FOR 2886"],"award-info":[{"award-number":["CRC1181 and FOR 2886"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["MASCARA"],"award-info":[{"award-number":["MASCARA"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited information exists about the very early forms of psoriatic arthritis. In particular, differences and responsiveness of patient-reported outcomes (PROs) in very early as compared to established PsA have not been investigated to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Cross-sectional and prospective longitudinal evaluation of PROs related to pain (VAS), physical function (HAQ-DI, SF-36 physical), mental function (SF-36 mental), impact of psoriatic skin (DLQI), joint (PsAID), and global disease (VAS) in two small prospective observational studies on secukinumab 300\u2009mg over 6\u2009months in very early disease patients (IVEPSA study,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200920) and established PsA (PSARTROS study,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200920). Cluster analysis was performed at baseline and 24-weeks of follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>While responses in pain and physical activity-related PROs to secukinumab were more pronounced in established PsA than a very early disease, effects on PROs related to general health perception, as well as those related to emotional and mental well-being, were modified in a similar way in very early disease and established PsA. Cluster analysis based on global disease activity and PROs showed that baseline clusters reflected very early disease and established PsA, while after secukinumab treatment these clusters were abolished and new clusters based on differential responses to physically and mentally oriented PROs formed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Inhibition of IL-17A by secukinumab leads to comprehensive improvement of general health perception and mental well-being in very early and established PsA, while overall responses in pain and physical activity are more pronounced in established disease. Most importantly, treatment restructures the original patients\u2019 clusters based on disease stage and leads to the formation of new clusters that reflect their response in physical and mental-orientated PROs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02483234\">NCT02483234<\/jats:ext-link>\n                      , registered 26 June 2015, retrospectively registered.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-020-02268-y","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T10:32:10Z","timestamp":1599733930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Secukinumab leads to shifts from stage-based towards response-based disease clusters\u2014comparative data from very early and established psoriatic arthritis"],"prefix":"10.1186","volume":"22","author":[{"given":"Eleni","family":"Kampylafka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"Tascilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Lerchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Linz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Zekovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Kleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel J.","family":"Hueber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"issue":"10","key":"2268_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"2","key":"2268_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.rdc.2016.01.002","volume":"42","author":"AM Orbai","year":"2016","unstructured":"Orbai AM, Ogdie A. Patient-reported outcomes in psoriatic arthritis. Rheum Dis Clin N Am. 2016;42(2):265\u201383.","journal-title":"Rheum Dis Clin N Am"},{"issue":"6","key":"2268_CR3","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","volume":"73","author":"L Gossec","year":"2014","unstructured":"Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, Maccarone M, Carton L, Otsa K, Sooaar I, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2268_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"2268_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","volume":"20","author":"E Kampylafka","year":"2018","unstructured":"Kampylafka E, d'Oliveira I, Linz C, Lerchen V, Stemmler F, Simon D, Englbrecht M, Sticherling M, Rech J, Kleyer A, et al. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study. Arthritis Res Ther. 2018;20(1):153.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2268_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","volume":"21","author":"E Kampylafka","year":"2019","unstructured":"Kampylafka E, Simon D, d'Oliveira I, Linz C, Lerchen V, Englbrecht M, Rech J, Kleyer A, Sticherling M, Schett G, et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21(1):178.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2268_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-018-1773-y","volume":"20","author":"LC Coates","year":"2018","unstructured":"Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, et al. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther. 2018;20(1):272.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2268_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13075-018-1610-3","volume":"20","author":"IB McInnes","year":"2018","unstructured":"McInnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, Pricop L, Jugl SM, Gandhi KK. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Res Ther. 2018;20(1):113.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2268_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","volume":"76","author":"V Strand","year":"2017","unstructured":"Strand V, Mease P, Gossec L, Elkayam O, van den Bosch F, Zuazo J, Pricop L, Mpofu S. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis. 2017;76(1):203\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"10136","key":"2268_CR10","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/S0140-6736(18)31217-0","volume":"391","author":"P Nash","year":"2018","unstructured":"Nash P. Psoriatic arthritis: novel targets add to a therapeutic renaissance. Lancet (London). 2018;391(10136):2187\u20139.","journal-title":"Lancet (London)"},{"issue":"3","key":"2268_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153\u201366.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"2268_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1080\/09546634.2017.1294727","volume":"28","author":"BE Elewski","year":"2017","unstructured":"Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatol Treat. 2017;28(6):492\u20139.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"2268_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jaad.2017.10.025","volume":"78","author":"L Puig","year":"2018","unstructured":"Puig L, Augustin M, Blauvelt A, Gottlieb AB, Vender R, Korman NJ, Thaci D, Zhao Y, Gilloteau I, Sherif B, et al. Effect of secukinumab on quality of life and psoriasis-related symptoms: a comparative analysis versus ustekinumab from the CLEAR 52-week study. J Am Acad Dermatol. 2018;78(4):741\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"2268_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41927-018-0030-y","volume":"2","author":"LC Coates","year":"2018","unstructured":"Coates LC, Orbai AM, Morita A, Benichou O, Kerr L, Adams DH, Shuler CL, Birt J, Helliwell PS. Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients\u2019 health-related quality of life and productivity. BMC Rheumatol. 2018;2:24.","journal-title":"BMC Rheumatol"},{"issue":"1","key":"2268_CR15","doi-asserted-by":"publisher","first-page":"e000415","DOI":"10.1136\/rmdopen-2016-000415","volume":"3","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Kavanaugh A, Coates LC, McInnes IB, Hojnik M, Zhang Y, Anderson JK, Dorr AP, Gladman DD. Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. RMD open. 2017;3(1):e000415.","journal-title":"RMD open"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02268-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02268-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02268-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T19:15:49Z","timestamp":1631128549000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02268-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2268"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02268-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-36002\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-36002\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided written informed consent and the institutional review board (IRB)\/ethics committee (Ethik-Kommission der Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg) approved the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}